Qualification of imaging biomarkers for oncology drug development.
about
DICOM for quantitative imaging biomarker development: a standards based approach to sharing clinical data and structured PET/CT analysis results in head and neck cancer researchMolecular imaging of breast cancer: present and future directionsRapid development of image analysis research tools: Bridging the gap between researcher and clinician with pyOsiriX.Imaging tumor metabolism using positron emission tomographyImaging biomarker roadmap for cancer studiesESR statement on the stepwise development of imaging biomarkers.Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastographyApparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study.Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy.Pharmacologic biomarkers in the development of stratified cancer medicine.False-negative MRI biomarkers of tumour response to targeted cancer therapeuticsA multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastomaSemi-quantitative parameter analysis of DCE-MRI revisited: monte-carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis.Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.The Accuracy of ADC Measurements in Liver Is Improved by a Tailored and Computationally Efficient Local-Rigid Registration AlgorithmPersonalized radiotherapy: concepts, biomarkers and trial designMetrology Standards for Quantitative Imaging Biomarkers.Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer ModelsMRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion castingAcute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.Incorporating prognostic imaging biomarkers into clinical practice.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome.Functional MRI and CT biomarkers in oncology.Towards Generation, Management, and Exploration of Combined Radiomics and Pathomics Datasets for Cancer Research.Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.Imaging biobanks in oncology: European perspective.Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.Translating imaging biomarkers into clinical practice.A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.Validating the Imaging Biomarker: The Proof of Efficacy and Effectiveness
P2860
Q24658635-958CC407-4341-458E-A163-BD07BBCD8CF3Q26999488-233A83A4-0623-4F10-BD91-40AB183EF91AQ27317305-0437F199-E618-457E-AE80-150E23A5D56CQ28085278-FCA3FB0F-DE4D-427B-ACD7-D148F055B137Q30242020-A1BE8C2E-2CC6-4BC2-A234-62A4AFE3E268Q30456007-2B935A25-1651-41E7-995D-44130285FDF3Q30764503-42CF3C81-6B0D-4873-986A-4D0E7AA0ACB5Q30959022-AFCF353C-E86E-45F0-891C-096AE2D0ABBCQ31121875-D18048E9-BCA5-4E3A-B026-3319481A46E3Q31123171-0FC15EED-4C68-4034-B19F-01C4137DD4D6Q33626476-40E3894D-310E-4C1D-A6B8-1261FB450A67Q34273077-3092DCB3-1C51-457C-BFE4-0EE140656978Q34702261-2CB6AFF1-EF4F-488F-9EC7-55CB05D29349Q34983575-7055CF01-5307-4519-97A8-166AFA6979C4Q35110740-71A7D626-4A42-4C03-86D2-3B1FBFDADE50Q35677936-D0C8A5C9-6DA4-44F6-B31A-A52D80704C84Q35708156-C0839353-C9D0-4FAF-BF48-DA82445BB00DQ36235704-FBF3E8A0-E901-4B92-ACB6-FCAE993FDFA6Q36336865-9A62DE31-369A-4477-921D-12962C6C725FQ36591139-F3B9EB05-9C81-4D88-8300-E89EA70ABA00Q36852895-29B2F25E-F3E0-4A2F-B8FE-C6DFDD509D99Q37182194-4EB391DA-C3DC-442C-8C57-E31B2EA11581Q37193816-3AE63280-0CD7-4A87-BD6A-67D4F0E1C1D2Q37533025-64DC70D9-4503-4CFA-90E0-5310AD4E3617Q38271116-DC543EC1-875D-48F4-BB60-4B558AD33263Q38314429-3FCD5786-D42F-4315-A706-39CDF5CDEB6CQ38621184-545C57A9-9C5E-46B3-886F-9D3E800630F2Q38775709-7EBA3B73-6596-41A6-8B54-7AE3098DDEE4Q47965726-6735628A-FADE-44DB-99E4-F8B42A357156Q48071853-916C0FAB-57C3-4389-B25B-27C4963D2E3AQ48863637-E9B8697A-5ABB-4A37-8CEA-8FEA055BFF75Q53911762-50720BE3-1AC6-4D0B-A178-198B381D778BQ55408134-7ED29BB1-4F55-413D-89DC-169C10CF99BBQ59308876-7CA62576-9942-4F71-8457-59A670D93FF9
P2860
Qualification of imaging biomarkers for oncology drug development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Qualification of imaging biomarkers for oncology drug development.
@en
Qualification of imaging biomarkers for oncology drug development.
@nl
type
label
Qualification of imaging biomarkers for oncology drug development.
@en
Qualification of imaging biomarkers for oncology drug development.
@nl
prefLabel
Qualification of imaging biomarkers for oncology drug development.
@en
Qualification of imaging biomarkers for oncology drug development.
@nl
P1476
Qualification of imaging biomarkers for oncology drug development
@en
P2093
Liisa Pylkkanen
P304
P356
10.1016/J.EJCA.2011.11.037
P577
2012-01-05T00:00:00Z